Table 3.
Predictors for intrahepatic distant recurrence by univariate Cox analysis
| Hazard ratio | 95% confidence interval | P value | |
|---|---|---|---|
| Combination with TAI | 0.39 | 0.19–0.79 | 0.0093 |
| Male | 1.21 | 0.55–2.69 | 0.64 |
| Age (per 1 year↑) | 1.02 | 0.97–1.07 | 0.36 |
| HCV versus HBV or NBNC | 1.45 | 0.63–3.34 | 0.39 |
| Previous treatment | 0.98 | 0.49–1.94 | 0.95 |
| Child–Pugh class (A versus B) | 1.13 | 0.52–2.46 | 0.76 |
| Stage ≥ III | 2.29 | 1.09–4.84 | 0.029 |
| Number of tumors >3 | 1.84 | 0.86–3.96 | 0.12 |
| Tumor diameter (per 1 mm↑) | 1.01 | 0.98–1.03 | 0.53 |
| AFP > 48 ng/mL | 1.02 | 0.48–2.16 | 0.96 |
| DCP > 89 mAU/mL | 1.24 | 0.59–2.61 | 0.56 |
| Creatinine (per 0.1 mg/dL↑) | 1.11 | 1.01–1.23 | 0.030 |
| Platelets (per 1 104/mm3↑) | 1.01 | 0.95–1.09 | 0.69 |
| ALT (per 1 IU/mL↑) | 1.01 | 0.99–1.01 | 0.51 |
| AST (per 1 IU/mL↑) | 1.00 | 0.99–1.01 | 0.87 |
| Albumin (per 1 g/dL↑) | 0.83 | 0.42–1.62 | 0.57 |
| Total bilirubin (per 1 mg/dL↑) | 1.05 | 0.57–1.92 | 0.88 |
| Prothrombin time (per 1%↑) | 1.01 | 0.98–1.04 | 0.49 |
| Dose of epirubicin (per 1 mg↑) | 1.02 | 1.00–1.03 | 0.023 |
| Dose of lipiodol (per 1 mL↑) | 1.02 | 0.94–1.12 | 0.61 |
AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DCP, des‐gamma‐carboxy prothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, both negative for HBV and HCV; TAI, transcatheter arterial infusion.